Michael D Kaytor

USPTO Granted Patents = 20 (Patent Applications = 13)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 2.5

ph-index = 4

Forward Citations = 67(Granted Patents)

Company Filing History:

12 out of 47

- Humanetics Corporation

University of Pennsylvania

patents

4. 1 out of 3

New Hope Research Foundation, Inc.

patents

5. 1 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12403195 - Sensitizing cells to proton radiation (2025-09-02),

2. 11779644 - Sensitizing cells to proton radiation (2023-10-10),

3. 11419827 - Protecting tissue and mitigating injury from radiation-induced ionizing events (2022-08-23),

4. 11129894 - Sensitizing cells to proton radiation (2021-09-28),

5. 10314812 - Suspension compositions of physiologically active phenolic compounds and methods of making and using the same (2019-06-11),

6. 10220018 - Method of mitigating long and short term detrimental effects of exposure to low dose ionizing radiation by administration of genistein (2019-03-05),

7. 10016514 - Polynucleotides, vectors and methods for insertion and expression of transgenes (2018-07-10),

8. 9993455 - Method of mitigating long term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein (2018-06-12),

9. 9937148 - Suspension compositions of physiologically active phenolic compounds and methods of making and using the same (2018-04-10),

10. 9782384 - Suspension compositions of physiologically active phenolic compounds and methods of making and using the same (2017-10-10),

11. 9623004 - Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy (2017-04-18),

12. 9623003 - Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein (2017-04-18),

13. 9387171 - Suspension compositions of physiologically active phenolic compounds and methods of making and using the same (2016-07-12),

14. 9084726 - Suspension compositions of physiologically active phenolic compounds and methods of making and using the same (2015-07-21),

15. 8957198 - Compositions, devices and methods for treatment of Huntington's disease through intracranial delivery of sirna (2015-02-17),

Title: Michael D Kaytor: Innovator in Radiation Therapy

Introduction

Michael D Kaytor, a talented inventor based in Maplewood, MN, has made significant contributions to the field of radiation therapy, holding an impressive total of 19 patents. His innovative work focuses on enhancing the effectiveness of proton radiation therapy and protecting tissues from radiation-induced injuries.

Latest Patents

Kaytor's latest patents include groundbreaking methods and materials designed to sensitize cells to proton radiation, thereby improving the treatment outcomes for tumor cells undergoing high linear energy transfer (LET) proton radiation therapy. Additionally, he has developed materials and methods aimed at reducing, preventing, or mitigating the effects of exposure to ionizing radiation. One of the notable strategies involves administering a nanoparticulate genistein composition to individuals identified as being exposed or at risk of exposure to ionizing radiation, such as proton radiation.

Career Highlights

Throughout his career, Michael D Kaytor has worked with notable companies in the medical technology space, including Humanetics Corporation and Medtronic, Inc. These opportunities have allowed him to leverage his innovative mindset and expertise in creating effective solutions for complex challenges in radiation therapy.

Collaborations

Kaytor's collaborative efforts have included working alongside talented professionals such as William Frederick Kaemmerer and John C Dykstra. These partnerships have contributed to advancing the research and development of methods that protect patients from the adverse effects of radiation.

Conclusion

Michael D Kaytor's contributions to radiation therapy demonstrate his commitment to improving patient outcomes through innovative solutions. With his extensive patent portfolio and collaboration with industry leaders, he continues to make strides in this vital area of medical research.

This text is generated by artificial intelligence and may not be accurate.